Knowledge centre

New EU HTA Regulations: Why It Matters to You and How Phastar Can Help You Be Prepared

1 minute read

Publications

Published: June 14th, 2024

EU HTA regulations are changing the way we conduct HTA submissions with EU regulators. Prior to the introduction of this legislation, submission to each member state’s regulatory body could be done in a staggered approach. This won’t be the case with EUnetHTA.

Read our latest article on the impact of these changes and how Phastar can help you be prepared.

Download Article

Related articles

Building Effective Partnerships Between Biotechs and CROs to Advance Clinical Development 
Publications

Building Effective Partnerships Between Biotechs and CROs to Advance Clinical Development 

July 21st, 2026 1 minute read

The biotech industry is evolving rapidly, with emerging companies leading the charge in clinical development. As outs...

Flexible Dose-Finding in Early-Phase Oncology Combination Studies Enabling Mid-Trial Dose Insertions to Improve Dose Recommendations
Publications

Flexible Dose-Finding in Early-Phase Oncology Combination Studies Enabling Mid-Trial Dose Insertions to Improve Dose Recommendations

April 2nd, 2026 1 minute read

Early-phase oncology combination trials often assume the optimal dose is already included in the dosing gri...

Leveraging Real-World Data for in-silico Trials: Enhancing Clinical Development and Regulatory Confidence
Publications

Leveraging Real-World Data for in-silico Trials: Enhancing Clinical Development and Regulatory Confidence

December 3rd, 2025 1 minute read

As the pharmaceutical landscape evolves, traditional clinical trial designs are increasingly complemented by innovati...